Mountain Pacific Investment Advisers LLC Sells 4,372 Shares of Danaher Corporation $DHR

Key Points

• Mountain Pacific Investment Advisers LLC has reduced its stake in Danaher Corporation by 2.1%, selling 4,372 shares, while still holding 203,943 shares with a value of approximately $40.3 million.
• Danaher reported earnings of $1.80 per share for the most recent quarter, exceeding analysts' estimates, and set its FY 2025 guidance at $7.700-$7.800 EPS.
• The company announced a quarterly dividend of $0.32 per share, reflecting an annualized dividend of $1.28, which equates to a yield of 0.6%.

Mountain Pacific Investment Advisers LLC reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 203,943 shares of the conglomerate's stock after selling 4,372 shares during the quarter. Danaher comprises about 2.9% of Mountain Pacific Investment Advisers LLC's portfolio, making the stock its 11th largest position. Mountain Pacific Investment Advisers LLC's holdings in Danaher were worth $40,287,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in DHR. Childress Capital Advisors LLC raised its position in Danaher by 10.6% during the second quarter. Childress Capital Advisors LLC now owns 1,797 shares of the conglomerate's stock valued at $355,000 after purchasing an additional 172 shares in the last quarter. OLD Point Trust & Financial Services N A raised its holdings in shares of Danaher by 24.9% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 1,406 shares of the conglomerate's stock worth $278,000 after buying an additional 280 shares in the last quarter. PFG Investments LLC lifted its position in shares of Danaher by 4.6% during the 2nd quarter. PFG Investments LLC now owns 5,233 shares of the conglomerate's stock worth $1,034,000 after buying an additional 228 shares during the last quarter. Liberty Capital Management Inc. boosted its stake in Danaher by 3.3% in the second quarter. Liberty Capital Management Inc. now owns 35,300 shares of the conglomerate's stock valued at $6,973,000 after buying an additional 1,128 shares in the last quarter. Finally, Bourgeon Capital Management LLC grew its position in Danaher by 1.7% in the second quarter. Bourgeon Capital Management LLC now owns 59,472 shares of the conglomerate's stock valued at $11,748,000 after acquiring an additional 1,013 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of NYSE:DHR opened at $212.92 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The firm has a market cap of $152.46 billion, a PE ratio of 45.30, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The firm's fifty day moving average is $199.85 and its 200-day moving average is $197.42.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company earned $1.72 EPS. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Bank of America dropped their target price on shares of Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a report on Monday, September 22nd. Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Wells Fargo & Company lowered their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.